ArticleBiosensors2026
Sensitive Detection of DJ-1 in Artificial Cerebrospinal Fluid Using a Portable GPTMS-Coordinated Gold Nanoparticle-Based Biosensor.
Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A highly selective and sensitive compact immunosensing strategy was developed for the determination of DJ-1, a potential biomarker of Parkinson's disease, one of the leading neurodegenerative disorders, using a portable potentiostat. Initially, screen-printed carbon electrodes (SPCEs) were modified with gold nanoparticles (AuNPs), followed by functionalization with 4-mercapto-1-butanol (MOH). Subsequently, the AuNPs-doped and hydroxyl-functionalized electrodes were treated with 3-glycidoxypropyltrimethoxysilane (GPTMS) to facilitate immobilization of anti-DJ-1 antibodies. Immobilization steps were monitored using electrochemical impedance spectroscopy (EIS) and cyclic voltammetry (CV) performed on a bench potentiostat, while the entire analytical performance of the developed biosensor system and its response in artificial cerebrospinal fluid (aCSF) were evaluated by monitoring cathodic current changes with a portable electrochemical reader. The resulting biorecognition element enabled the detection of DJ-1 within the concentration range of 0.001 to 0.3 ng/mL, based on cathodic current changes, achieving a limit of detection as low as 0.00059 ng/mL. Surface morphology and elemental composition alterations were characterized by scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), and energy-dispersive X-ray spectroscopy (EDX). A notable advantage of this GPTMS@AuNPs-based biosensor system is its prolonged storage stability and its capability to accurately quantify DJ-1 in artificial cerebrospinal fluid samples, with recovery rates ranging from 98.66% to 123.3%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.